Jared Clark, FDA GMP compliance consultant at Certify Consulting and theGMPconsultant.com, provides pharmaceutical GMP remediation and audit preparation services — warning letter response and CAPA consulting, FDA inspection readiness, and 21 CFR Part 211 documentation.
Most pharmaceutical GMP engagements start after an FDA Form 483 or warning letter, not before one. Responding effectively means more than fixing the cited observation — FDA expects a root-cause investigation, a documented Corrective and Preventive Action (CAPA) plan with defined timelines, and evidence the correction is systemic rather than a one-time fix. A consultant who has actually written warning letter responses knows which commitments FDA will accept and which invite a follow-up inspection.
Routine surveillance inspections and pre-approval inspections (PAI) tied to a pending NDA or ANDA carry different stakes and different scrutiny. PAI readiness means the specific batch records, stability data, and process validation reports referenced in the application must reconcile exactly with what's on the manufacturing floor. Preparation includes a full mock inspection, employee interview readiness, and a records room organized so any requested document — including the exact validation runs cited in the submission — can be located within minutes.
21 CFR Part 211 requires a documentation system considerably more rigorous than 21 CFR Part 111 for supplements: master production and control records, batch production records reconciled to the master, process validation protocols and reports, cleaning validation, environmental monitoring data, and a stability program supporting expiration dating. A consultant builds these systems so that documentation happens as a byproduct of doing the work correctly — not as a separate paperwork exercise staff routinely fall behind on.
See how this compares to the first-90-days framework used for dietary supplement manufacturers, or read about what makes the best GMP consultant for either industry.